aprea.com (APRE) - Gross Profit Margin

Official company branding of Aprea Therapeutics (APRE)

Aprea Therapeutics focuses on independent trials of DNA regeneration drugs, limiting its partnerships to oncology centers. These projects carry the risk of early-phase failure and a high burn rate. Robotic systems accelerate molecule synthesis, optimizing staffing levels. The current gross margin demonstrates financial efficiency, while the value of -574.50 indicates the business's profitability status.

APRE (aprea.com) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for aprea.com (APRE)

- market price and analyst price targets:
Basic company analysis:Aprea Therapeutics (APRE)
Manufactured products of Aprea Therapeutics

Aprea Therapeutics (APRE) focuses on developing innovative DDR drugs to combat tumor resistance within the R&D stage. Gross margin measures production efficiency, reflecting the portion of revenue remaining after deducting all direct costs of product creation. Analyzing relative gross margin allows an investor to promptly detect changes in operating profitability and assess the risk of capital freeze within the startup.